NUSINERSEN SODIUM
| Brand name | SPINRAZA |
|---|---|
| Active ingredient | NUSINERSEN SODIUM |
| Strength | EQ 50MG BASE/5ML (EQ 10MG BASE/ML) |
| Dosage form | SOLUTION |
| Route | INTRATHECAL |
| Modality | Small molecule |
| FDA approval | March 2026 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 8361977 | December 2030 | substance, product |
| 8980853 | November 2030 | use U-1941 |
| 9717750 | June 2030 | use U-1942 |
| 7838657 | July 2027 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.